Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ZYC300

A plasmid DNA encoding an inactivated form of the carcinogen activator cytochrome P450 1B1 (CYP1B1) encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles with potential antineoplastic activity. Vaccination with ZYC300 may stimulate the immune system to elicit a cytotoxic T lymphocyte (CTL) response against the tumor-associated antigen (TAA) CYP1B1, which may result in the lysis of tumor cells expressing CYP1B1. CYP1B1, an extrahepatic monooxygenase of the cytochrome P450 family, is overexpressed in many cancers with only restricted expression in normal tissues.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

ZYC300

Search NCI's Drug Dictionary